risperidone has been researched along with Basal Ganglia Diseases in 216 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 8-week (trial timepoints: baseline, week 4, week 8), double-blind, placebo-controlled clinical trial randomized patients with schizophrenia in a 1:1 ratio to compare the efficacy and safety of 600 mg twice a day of PEA and matched placebo alongside a stable dose of risperidone." | 9.51 | Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. ( Akhondzadeh, S; Bagheri, S; Khodaei Ardakani, MR; Moradi, K; Namaei, P; Salehi, A; TaghaviZanjani, F, 2022) |
| "The risperidone maintenance treatment in schizophrenia study was designed to identify the duration of maintenance treatment required with an initial therapeutic dose in contrast to reducing the dose over time." | 9.22 | Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study. ( Bo, QJ; Li, AN; Li, XB; Ma, X; Wang, CY; Wang, ZM, 2016) |
| "Body iron stores are inversely related to risperidone-induced weight gain, even after extended treatment and despite adequate iron intake." | 9.22 | Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. ( Arnold, LE; Calarge, CA; Murry, DJ; Ziegler, EE, 2016) |
| "The aim of this randomized, parallel-arm trial was to study the effect of treating subsyndromal delirium with risperidone on the incidence of clinical delirium in elderly patients who underwent on-pump cardiac surgery." | 9.16 | Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly: a randomized trial. ( Hakim, SM; Naoum, DO; Othman, AI, 2012) |
| "Perospirone was as effective as risperidone against positive and negative symptoms in patients with schizophrenia." | 9.14 | Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. ( Kato, M; Kinoshita, T; Kishimoto, T; Koh, J; Matsumoto, N; Morikawa, M; Okugawa, G; Shinosaki, K; Wakeno, M; Yoneda, H, 2009) |
| "This was a randomized, flexible-dose, rater-blind, parallel-group, quasi-naturalistic trial comparing the efficacy, safety, and tolerability of quetiapine, risperidone, and olanzapine in patients with schizophrenia hospitalized for severe psychotic symptoms." | 9.13 | A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. ( Parrinello, G; Sacchetti, E; Valsecchi, P, 2008) |
| "This multicentre, observational, prospective, nonrandomized study compared the effectiveness and tolerability of quetiapine and risperidone in the acute and long-term treatment of schizophrenia in a clinical setting." | 9.13 | A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. ( Cañas, F; Perez, V; Tafalla, M, 2008) |
| "To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia." | 9.12 | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. ( Hamer, RM; Lieberman, JA; Sweitzer, DE; Zhong, KX, 2006) |
| "The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders." | 9.12 | Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. ( Gunduz-Bruce, H; Kane, JM; Khadivi, A; Lesser, ML; Lorell, BS; McCormack, J; Mendelowitz, A; Miller, R; Napolitano, B; Patel, RC; Robinson, DG; Schooler, NR; Sevy, SM; Soto-Perello, JM; Woerner, MG, 2006) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 9.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| " Dementia patients with behavioral and psychological symptoms received risperidone for 3 months." | 9.11 | Open-label, observational study of the effects of risperidone on the behavioral and psychological symptoms of dementia and caregiver stress in the community setting. ( Antonio Burón, J; Arriola, E; Gallego, R; Ignacio Diago, J, 2005) |
| "Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials." | 9.11 | Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. ( Kurz, A; Schmitt, A; Schwalen S, S, 2005) |
| "This randomized, double-blind, placebo-controlled trial examined the efficacy and safety of risperidone in the treatment of aggression, agitation, and psychosis in elderly nursing-home patients with dementia." | 9.10 | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. ( Ames, D; Brodaty, H; Clarnette, R; Grossman, F; Kirwan, J; Lee, E; Lyons, B; Snowdon, J; Woodward, M, 2003) |
| "Aripiprazole is effective, safe, and well tolerated for the positive and negative symptoms in schizophrenia and schizoaffective disorder." | 9.10 | Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J, 2003) |
| "Data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce." | 9.10 | Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. ( Bensason, D; Carmon, E; Martin, A; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction." | 9.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia." | 9.09 | Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. ( Adler, CM; Breier, AF; Clifton, A; Elman, I; Lafargue, RT; Malhotra, AK; Pickar, D; Pinals, DA; Su, TP, 1999) |
| "We report the findings from the first large, double-blind, placebo-controlled study conducted to evaluate the efficacy and safety of risperidone in the treatment of psychotic and behavioral symptoms in institutionalized elderly patients with dementia." | 9.09 | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. ( Brecher, M; Clyde, C; Jeste, DV; Katz, IR; Mintzer, JE; Napolitano, J, 1999) |
| "The authors evaluated the safety, tolerability, and efficacy of risperidone in 103 elderly patients (mean age, 71 years) with schizophrenia (75%) or schizoaffective disorder (25%)." | 9.09 | Risperidone in the treatment of elderly patients with psychotic disorders. ( Brecher, M; Brenner, R; Kasckow, J; Kunik, M; Madhusoodanan, S; Negrón, AE; Pomara, N, 1999) |
| "The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia." | 9.09 | Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 9.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "From a cohort of 126 patients, 2 groups of 19 first-episode DSM-III-R/DSM-IV schizophrenia patients matched for age, gender, length of illness, and length of treatment and treated with either a typical antipsychotic or risperidone for a minimum of 1 year were compared on a number of outcome dimensions during their course of treatment and at follow-up." | 9.09 | A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. ( Kotteda, V; Malla, AK; Norman, RM; Scholten, DJ; Zirul, S, 2001) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 9.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "We randomly assigned 38 adolescents (33 boys; 10 subjects with slightly subaverage IQ, 14 with borderline IQ, and 14 with mild mental retardation), who were hospitalized for treatment of psychiatric disorders associated with severe aggression, to receive risperidone or placebo." | 9.09 | A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. ( Buitelaar, JK; Cohen-Kettenis, P; Melman, CT; van der Gaag, RJ, 2001) |
| "This prospective, double-blind, multicenter, parallel-group study compared the efficacy and safety of therapeutic doses of clozapine and risperidone in patients with severe chronic schizophrenia and poor previous treatment response." | 9.09 | A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. ( Azorin, JM; Bourdeix, I; Giguere, M; Péré, JJ; Remington, G; Spiegel, R; Vanelle, JM, 2001) |
| "The purpose of this study was to determine the prevalence of extrapyramidal signs or symptoms (EPS) and clinical symptoms in first-episode schizophrenia, before any treatment, during and after treatment with a novel antipsychotic, risperidone." | 9.08 | Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. ( Good, KP; Honer, WG; Kopala, LC, 1997) |
| "In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo." | 9.08 | The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. ( Chouinard, G; Davis, JM; Marder, SR, 1997) |
| " Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks." | 9.08 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 8.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| " The Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities comprised academic clinicians with at least 10 years' experience in the field of mental retardation and developmental disabilities." | 8.82 | Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. ( Aman, MG; Gharabawi, GM, 2004) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 8.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "This study evaluates the relative effectiveness and side-effects of risperidone as compared with conventional neuroleptics in the treatment of schizophrenia, by meta-analysis of 11 double-blind, randomized controlled trials." | 8.79 | Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. ( Song, F, 1997) |
| "To examine clinical outcomes in Asian patients with schizophrenia receiving monotherapy with olanzapine, risperidone or typical antipsychotics in naturalistic settings." | 7.73 | Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. ( Dyachkova, Y; Habil, H; Lee, C; Lee, P; Wu, KH, 2006) |
| "To evaluate the safety and tolerability of olanzapine in the treatment of elderly patients with schizophrenia." | 7.72 | Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study. ( Ciudad, A; Gómez, JC; Montes, JM; Olivares, JM, 2004) |
| "A case of urinary retention emerging after fluoxetine (20 mg/day) addition to low risperidone doses (2 mg/day) is presented." | 7.71 | Urinary retention caused after fluoxetine-risperidone combination. ( Bozikas, V; Karavatos, A; Petrikis, P, 2001) |
| " Six healthy volunteers, five clozapine- and five risperidone-treated subjects with DSM-IV schizophrenia were studied." | 7.70 | 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. ( Acton, PD; Busatto, GF; Costa, DC; Ell, PJ; Gacinovic, S; Kerwin, RW; Mertens, J; Mulligan, R; Pilowsky, LS; Terrière, D; Travis, MJ, 1998) |
| "The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia." | 7.70 | Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D, 2000) |
| " We conducted an 8-week, rater-blinded, randomized trial, administering flexibly dosed risperidone, yokukansan, or fluvoxamine." | 6.78 | Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. ( Kurita, M; Nishino, S; Numata, Y; Okubo, Y; Sato, T; Takeyoshi, K; Tateno, A; Teranishi, M, 2013) |
| "Dementia is associated with progressive cognitive impairment and behavioral and psychological symptoms." | 6.71 | Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia. ( Diago, JI; Durán, JC; Gallego, R; Greenspan, A; Martinez, G, 2005) |
| "Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments." | 6.70 | Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. ( Ancione, M; Avenoso, A; Facciolà, G; Madia, AG; Perucca, E; Salemi, M; Scordo, MG; Spina, E, 2001) |
| " Gradual dosage titration over the first 3 days of treatment was well-tolerated in both groups." | 6.69 | Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. ( Nair, NP, 1998) |
| "This 8-week (trial timepoints: baseline, week 4, week 8), double-blind, placebo-controlled clinical trial randomized patients with schizophrenia in a 1:1 ratio to compare the efficacy and safety of 600 mg twice a day of PEA and matched placebo alongside a stable dose of risperidone." | 5.51 | Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. ( Akhondzadeh, S; Bagheri, S; Khodaei Ardakani, MR; Moradi, K; Namaei, P; Salehi, A; TaghaviZanjani, F, 2022) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 5.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients." | 5.31 | Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). ( Edgell, E; García-Cabeza, I; Gómez, JC; González de Chavez, M; Sacristán, JA, 2001) |
| "Risperidone may prove to be an effective alternative to haloperidol in delirious patients, especially the elderly and the severely medically ill, who are more prone to adverse effects." | 5.30 | Use of risperidone in delirium: case reports. ( Masand, PS; Sipahimalani, A, 1997) |
| "The risperidone maintenance treatment in schizophrenia study was designed to identify the duration of maintenance treatment required with an initial therapeutic dose in contrast to reducing the dose over time." | 5.22 | Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study. ( Bo, QJ; Li, AN; Li, XB; Ma, X; Wang, CY; Wang, ZM, 2016) |
| "Body iron stores are inversely related to risperidone-induced weight gain, even after extended treatment and despite adequate iron intake." | 5.22 | Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. ( Arnold, LE; Calarge, CA; Murry, DJ; Ziegler, EE, 2016) |
| "The aim of this randomized, parallel-arm trial was to study the effect of treating subsyndromal delirium with risperidone on the incidence of clinical delirium in elderly patients who underwent on-pump cardiac surgery." | 5.16 | Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly: a randomized trial. ( Hakim, SM; Naoum, DO; Othman, AI, 2012) |
| "Perospirone was as effective as risperidone against positive and negative symptoms in patients with schizophrenia." | 5.14 | Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. ( Kato, M; Kinoshita, T; Kishimoto, T; Koh, J; Matsumoto, N; Morikawa, M; Okugawa, G; Shinosaki, K; Wakeno, M; Yoneda, H, 2009) |
| "This was a randomized, flexible-dose, rater-blind, parallel-group, quasi-naturalistic trial comparing the efficacy, safety, and tolerability of quetiapine, risperidone, and olanzapine in patients with schizophrenia hospitalized for severe psychotic symptoms." | 5.13 | A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. ( Parrinello, G; Sacchetti, E; Valsecchi, P, 2008) |
| "This multicentre, observational, prospective, nonrandomized study compared the effectiveness and tolerability of quetiapine and risperidone in the acute and long-term treatment of schizophrenia in a clinical setting." | 5.13 | A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. ( Cañas, F; Perez, V; Tafalla, M, 2008) |
| "To compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia." | 5.12 | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. ( Hamer, RM; Lieberman, JA; Sweitzer, DE; Zhong, KX, 2006) |
| "The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders." | 5.12 | Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. ( Gunduz-Bruce, H; Kane, JM; Khadivi, A; Lesser, ML; Lorell, BS; McCormack, J; Mendelowitz, A; Miller, R; Napolitano, B; Patel, RC; Robinson, DG; Schooler, NR; Sevy, SM; Soto-Perello, JM; Woerner, MG, 2006) |
| " However, the results suggest that quetiapine, when given within the recommended dosage range, has a benign EPS profile, with potentially greater tolerability and comparable efficacy to risperidone in older outpatients with psychotic disorders." | 5.11 | A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. ( Mintzer, JE; Mullen, JA; Sweitzer, DE, 2004) |
| "Neuroleptic monotherapy with risperidone was administered to schizophrenia patients in a 6-week open dose clinical trial." | 5.11 | Risperidone plasma levels, clinical response and side-effects. ( Möller, HJ; Müller, N; Müller-Arends, A; Riedel, M; Schwarz, MJ; Spellmann, I; Strassnig, M; Weber, K; Zach, J, 2005) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 5.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| "In this 6-week double-blind study, 30 patients with DSM-IV schizophrenia who had partial response to clozapine despite being treated for a mean of 32 months were randomly assigned to risperidone (N = 16) up to 6 mg/day or placebo (N = 14)." | 5.11 | A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. ( Alptekin, K; Anil Yağcioğlu, AE; Ertuğrul, A; Göğüş, A; Jayathilake, K; Kivircik Akdede, BB; Meltzer, HY; Tümüklü, M; Tunca, Z; Turgut, TI; Yazici, MK, 2005) |
| "The maintained antipsychotic efficacy of risperidone long-acting injectable (RLAI) was investigated in patients with schizophrenia or other psychoses who were transitioned directly from their previous antipsychotic medication." | 5.11 | Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. ( Llorca, PM; Martin, SD; Medori, R; Möller, HJ; Parellada, E; Sacchetti, E, 2005) |
| " Dementia patients with behavioral and psychological symptoms received risperidone for 3 months." | 5.11 | Open-label, observational study of the effects of risperidone on the behavioral and psychological symptoms of dementia and caregiver stress in the community setting. ( Antonio Burón, J; Arriola, E; Gallego, R; Ignacio Diago, J, 2005) |
| "Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials." | 5.11 | Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. ( Kurz, A; Schmitt, A; Schwalen S, S, 2005) |
| "In a double-blind, fixed-dose study, 49 acutely psychotic, neuroleptic-naive patients who were admitted for the first time and who met DSM-IV criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder were randomly assigned to 2 or 4 mg/day of risperidone." | 5.10 | Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. ( Berger, G; Gekle, W; Hofer, H; Latour, G; Marder, SR; Merlo, MC; Panhuber, I; Ventura, J, 2002) |
| "This randomized, double-blind, placebo-controlled trial examined the efficacy and safety of risperidone in the treatment of aggression, agitation, and psychosis in elderly nursing-home patients with dementia." | 5.10 | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. ( Ames, D; Brodaty, H; Clarnette, R; Grossman, F; Kirwan, J; Lee, E; Lyons, B; Snowdon, J; Woodward, M, 2003) |
| "Aripiprazole is effective, safe, and well tolerated for the positive and negative symptoms in schizophrenia and schizoaffective disorder." | 5.10 | Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J, 2003) |
| "Data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce." | 5.10 | Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. ( Bensason, D; Carmon, E; Martin, A; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction." | 5.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "This 3-week randomized, double-blind, placebo-controlled study included 156 bipolar disorder patients with a current manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol." | 5.10 | Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. ( Bowden, CL; Ghaemi, SN; Grossman, F; Okamoto, A; Sachs, GS, 2002) |
| "Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia." | 5.09 | Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. ( Adler, CM; Breier, AF; Clifton, A; Elman, I; Lafargue, RT; Malhotra, AK; Pickar, D; Pinals, DA; Su, TP, 1999) |
| "We report the findings from the first large, double-blind, placebo-controlled study conducted to evaluate the efficacy and safety of risperidone in the treatment of psychotic and behavioral symptoms in institutionalized elderly patients with dementia." | 5.09 | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. ( Brecher, M; Clyde, C; Jeste, DV; Katz, IR; Mintzer, JE; Napolitano, J, 1999) |
| "The authors evaluated the safety, tolerability, and efficacy of risperidone in 103 elderly patients (mean age, 71 years) with schizophrenia (75%) or schizoaffective disorder (25%)." | 5.09 | Risperidone in the treatment of elderly patients with psychotic disorders. ( Brecher, M; Brenner, R; Kasckow, J; Kunik, M; Madhusoodanan, S; Negrón, AE; Pomara, N, 1999) |
| "The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia." | 5.09 | Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 5.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "Effects of flexible doses of risperidone and haloperidol were compared in 77 psychotic patients (83% with chronic schizophrenia) with disturbing neuroleptic-induced EPS (risperidone 40 patients, haloperidol 37)." | 5.09 | Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. ( de Groot, IW; Haffmans, PM; Heck, AH; Hoencamp, E, 2000) |
| "From a cohort of 126 patients, 2 groups of 19 first-episode DSM-III-R/DSM-IV schizophrenia patients matched for age, gender, length of illness, and length of treatment and treated with either a typical antipsychotic or risperidone for a minimum of 1 year were compared on a number of outcome dimensions during their course of treatment and at follow-up." | 5.09 | A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. ( Kotteda, V; Malla, AK; Norman, RM; Scholten, DJ; Zirul, S, 2001) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 5.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "We randomly assigned 38 adolescents (33 boys; 10 subjects with slightly subaverage IQ, 14 with borderline IQ, and 14 with mild mental retardation), who were hospitalized for treatment of psychiatric disorders associated with severe aggression, to receive risperidone or placebo." | 5.09 | A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. ( Buitelaar, JK; Cohen-Kettenis, P; Melman, CT; van der Gaag, RJ, 2001) |
| "This prospective, double-blind, multicenter, parallel-group study compared the efficacy and safety of therapeutic doses of clozapine and risperidone in patients with severe chronic schizophrenia and poor previous treatment response." | 5.09 | A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. ( Azorin, JM; Bourdeix, I; Giguere, M; Péré, JJ; Remington, G; Spiegel, R; Vanelle, JM, 2001) |
| "The hypothesis that differences in drug effects of risperidone and haloperidol on negative symptoms in schizophrenia are secondary to effects on positive, extrapyramidal, and depressive symptoms was investigated by means of an analysis of the data from the USA-Canada risperidone double-blind randomized clinical trial of 523 chronic schizophrenic patients." | 5.08 | A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. ( Borison, RL; Chouinard, G; Möller, HJ; Müller, H; Schooler, NR, 1995) |
| "The purpose of this study was to determine the prevalence of extrapyramidal signs or symptoms (EPS) and clinical symptoms in first-episode schizophrenia, before any treatment, during and after treatment with a novel antipsychotic, risperidone." | 5.08 | Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. ( Good, KP; Honer, WG; Kopala, LC, 1997) |
| "In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo." | 5.08 | The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. ( Chouinard, G; Davis, JM; Marder, SR, 1997) |
| " Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks." | 5.08 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 4.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| " The Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities comprised academic clinicians with at least 10 years' experience in the field of mental retardation and developmental disabilities." | 4.82 | Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. ( Aman, MG; Gharabawi, GM, 2004) |
| "Advances in the assessment of the behavioral and psychological symptoms of dementia (BPSD) have been employed in large-scale clinical trials of new antipsychotic medications such as risperidone." | 4.81 | Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. ( De Deyn, PP; Wirshing, WC, 2001) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 4.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| "The objective of this meta-analysis is to summarize the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics." | 4.80 | Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. ( Abraham, D; Kissling, W; Leucht, S; Pitschel-Walz, G, 1999) |
| " Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia." | 4.80 | Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000) |
| "This study evaluates the relative effectiveness and side-effects of risperidone as compared with conventional neuroleptics in the treatment of schizophrenia, by meta-analysis of 11 double-blind, randomized controlled trials." | 4.79 | Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. ( Song, F, 1997) |
| "To describe a cohort of young users of risperidone and quetiapine in the province of Manitoba (Canada) and assess the risk for movement disorders in the two treatments." | 3.85 | Movement Disorders in Children and Adolescents Receiving Antipsychotic Pharmacotherapy: A Population-Based Study. ( Alessi-Severini, S; Biscontri, RG; Bugden, S; Collins, DM; Jha, S; Katz, LY, 2017) |
| "We investigated the relationship between basal ganglia volume and treatment response to the atypical antipsychotic medication risperidone in unmedicated patients with schizophrenia." | 3.80 | Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. ( Bolding, MS; Clark, DG; Hutcheson, NL; Lahti, AC; White, DM, 2014) |
| "Compared to traditional neuroleptics, most of the new antipsychotics are characterized by a low extrapyramidal side effect (EPS) liability and varying antipsychotic efficacy." | 3.77 | New antipsychotics: classification, efficacy, and adverse effects. ( Gerlach, J, 1991) |
| "Thirteen subjects aged 50 (mean +/- standard deviation age: 62 +/- 9 years) with schizophrenia or schizoaffective disorder who were receiving risperidone." | 3.75 | Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. ( Graff-Guerrero, A; Kapur, S; Mamo, DC; Mulsant, BH; Pollock, BG; Uchida, H, 2009) |
| "We report the case of a 16-year-old male with Mucopolysaccharidosis III type A (Sanfilippo syndrome) who was commenced on risperidone for behaviour management." | 3.75 | Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III. ( Sillence, D; Tchan, MC, 2009) |
| "We identified patients with schizophrenia from outpatient clinics in the Veterans Health Administration (VA) and defined initiation of olanzapine or risperidone as patients who were not on any antipsychotics for 6 months and subsequently initiated on the target drug between 1/4/1999 and 31/3/2000." | 3.73 | Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. ( Huang, YH; Kazis, L; Lee, AF; Miller, DR; Qian, S; Ren, XS, 2005) |
| "After achieving stabilization with one of the doses, nine patients with a diagnosis of schizophrenia or schizoaffective disorder underwent [(11)C]raclopride PET to measure D(2) occupancy." | 3.73 | A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ( Kapur, S; Labelle, A; Mamo, D; Mann, S; Mannaert, E; Reiss, J; Remington, G; Shammi, C, 2006) |
| "To examine clinical outcomes in Asian patients with schizophrenia receiving monotherapy with olanzapine, risperidone or typical antipsychotics in naturalistic settings." | 3.73 | Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. ( Dyachkova, Y; Habil, H; Lee, C; Lee, P; Wu, KH, 2006) |
| "To evaluate the safety and tolerability of olanzapine in the treatment of elderly patients with schizophrenia." | 3.72 | Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study. ( Ciudad, A; Gómez, JC; Montes, JM; Olivares, JM, 2004) |
| "A case of urinary retention emerging after fluoxetine (20 mg/day) addition to low risperidone doses (2 mg/day) is presented." | 3.71 | Urinary retention caused after fluoxetine-risperidone combination. ( Bozikas, V; Karavatos, A; Petrikis, P, 2001) |
| "In 20 patients with schizophrenia [Diagnostic and Statistical Manual of Mental Disorders (Third Edition-Revised)] treated with mean daily doses of risperidone ranging from 0." | 3.70 | Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients. ( Dähne, I; Dresel, S; Hahn, K; Mager, T; Scherer, J; Tatsch, K, 1998) |
| " Six healthy volunteers, five clozapine- and five risperidone-treated subjects with DSM-IV schizophrenia were studied." | 3.70 | 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. ( Acton, PD; Busatto, GF; Costa, DC; Ell, PJ; Gacinovic, S; Kerwin, RW; Mertens, J; Mulligan, R; Pilowsky, LS; Terrière, D; Travis, MJ, 1998) |
| "The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia." | 3.70 | Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D, 2000) |
| "The objectives of this study were to determine the doses of olanzapine (OLZ), risperidone (RIS), and haloperidol (HAL) used in clinical practice in outpatients with schizophrenia and the rates of occurrence of extrapyramidal symptoms (EPS) and other adverse events, clinical response, and use of concomitant medications." | 3.70 | Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. ( Gómez, JC; Gregor, KJ; Montejo, AL; Sacristán, JA; Vieta, E, 2000) |
| "Patients in the acute phase of mania were assigned into two parallel groups given either lithium (blood level of 0." | 3.11 | Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial. ( Abedini, T; Akhondzadeh, S; Ardakani, MK; Ghannadi, F; Hosseyni, R; Moghaddam, HS; Talaei, A, 2022) |
| " Moreover, its ability to predict actigraphy records is similar to the predictive power of pharmacokinetic parameters (24%)." | 2.79 | Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial. ( Arnaiz, JA; Bernardo, M; Bioque, M; de Bobadilla, RF; Ferrando, E; Gassó, P; Lafuente, A; Mas, S; Papagianni, K, 2014) |
| " We conducted an 8-week, rater-blinded, randomized trial, administering flexibly dosed risperidone, yokukansan, or fluvoxamine." | 2.78 | Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. ( Kurita, M; Nishino, S; Numata, Y; Okubo, Y; Sato, T; Takeyoshi, K; Tateno, A; Teranishi, M, 2013) |
| " A dose-response effect on impairment of balance was observed that followed the expected time course of the drug pharmacokinetics." | 2.77 | Influence of risperidone on balance control in young healthy individuals. ( Cohen, H; Corbeil, P; Pourcher, E; Rodrigue, J; Simoneau, M, 2012) |
| "Risperidone was generally well tolerated." | 2.73 | Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. ( Haas, M; Karcher, K; Pandina, GJ, 2008) |
| "Risperidone was generally well tolerated." | 2.71 | Risperidone in combination with mood stabilizers for acute mania: a multicentre, open study. ( Bahk, WM; Choi, SK; Kim, KS; Kim, YH; Lee, C; Lee, YH; Pae, CU; Song, HK; Yoon, JS, 2004) |
| " The failure to confirm previous claims of greater improvement on either risperidone or olanzapine in patients with a first episode of psychosis may be the result of methodological bias introduced by unequal dosing between the two drugs or the use of chronically ill and treatment-refractory patients in previous studies." | 2.71 | A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition. ( Haricharan, R; Malla, A; Manchanda, R; Norman, R; Scholten, D; Takhar, J; Townsend, L, 2004) |
| " The aim of this study was to compare the effectiveness and tolerability of topiramate and divalproex in combination with risperidone for treating acute mania patients in a naturalistic treatment setting." | 2.71 | Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. ( Bahk, WM; Choi, SK; Chung, SK; Jon, DI; Lee, JS; Pae, CU; Paik, IH; Shin, YC; Woo, JM; Yoon, BH, 2005) |
| "Treatment with risperidone for either 3 or 6 weeks in an open trial significantly reduced total and subscales scores on the PANSS and on the PTSD-I and CGI-S when compared to baseline scores in patients with psychotic PTSD." | 2.71 | Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. ( Kozarić-Kovacić, D; Mück-Seler, D; Pivac, N; Rothbaum, BO, 2005) |
| "Dementia is associated with progressive cognitive impairment and behavioral and psychological symptoms." | 2.71 | Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia. ( Diago, JI; Durán, JC; Gallego, R; Greenspan, A; Martinez, G, 2005) |
| "Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments." | 2.70 | Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. ( Ancione, M; Avenoso, A; Facciolà, G; Madia, AG; Perucca, E; Salemi, M; Scordo, MG; Spina, E, 2001) |
| "Risperidone was well tolerated; side effects were few and generally mild." | 2.70 | Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). ( Benabarre, A; Colom, F; Fernández, A; Gastó, C; Herraiz, M; Martínez-Arán, A; Reinares, M; Vieta, E, 2001) |
| "Risperidone treatment was well tolerated, and no clinically relevant changes in EPS." | 2.70 | Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. ( Ertl, MG; Haushofer, M; Kraxberger, E; Masching, AJ; Rainer, MK, 2001) |
| " Gradual dosage titration over the first 3 days of treatment was well-tolerated in both groups." | 2.69 | Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. ( Nair, NP, 1998) |
| "Treatment with risperidone, 6 mg/day, is likely to induce unnecessarily high D2 receptor occupancy, with a consequent risk of extrapyramidal side effects." | 2.69 | Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. ( Eriksson, B; Farde, L; Halldin, C; Nyberg, S; Oxenstierna, G, 1999) |
| "Risperidone was significantly superior to placebo in its effect on the Aberrant Behaviour Checklist and the Clinical Global Impression." | 2.67 | Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. ( Buttiëns, M; Dierick, G; Geutjens, J; Heylen, S; Sieben, G; Thiry, P; Vanden Borre, R; Vermote, R, 1993) |
| "Aripiprazole has the most consistent evidence of symptom improvement; however, this improvement is small." | 2.53 | Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use. ( Cocker, KE; Reese, TR; Thiel, DJ, 2016) |
| " However, there are still significant adverse effects and toxicities with this class of medications." | 2.43 | Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? ( Dubois, D, 2005) |
| "Patients with Alzheimer's disease exhibit aggressive behavior, and alterations in their serotonergic function have been identified." | 2.41 | Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. ( Mintzer, JE, 2001) |
| "In 2 pivotal trials comparing risperidone with placebo, the risk of adverse events was similar in both treatment groups when risperidone was given at the optimal clinical dose (1 mg/day)." | 2.41 | Long-term safety of risperidone. ( Davidson, M, 2001) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| "Of the 17 children who developed extrapyramidal disorders, all had minor or moderate symptoms and only five required a symptomatic treatment." | 1.51 | Risperidone medication errors in children: an analysis of French poison centres data. ( Boels, D; Kassai, B; Nisse, P; Paret, N; Patat, AM; Torrents, R; Vial, T; Villa, A, 2019) |
| " Antipsychotics have important adverse effects, and systematic monitoring of drug safety is infrequently performed." | 1.46 | Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study. ( Hammer, T; Ho, J; Patten, S; Pringsheim, T; Sarna, JR, 2017) |
| "Antipsychotic drugs can induce various undesirable adverse motor reactions, such as extrapyramidal side effects (EPS)." | 1.43 | Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations? ( Gründer, G; Haen, E; Hiemke, C; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Veselinovic, T, 2016) |
| " However, researchers lack a standardised method to compare different drugs for common adverse effects on the nervous system." | 1.39 | Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale. ( Menniti, FS; Papa, SM; Schmidt, CJ; Shaffer, CL; Uthayathas, S, 2013) |
| "Weight gain was found to be lower in the elderly for antipsychotic drugs, in particular for olanzapine." | 1.39 | Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. ( Baumann, P; Greil, W; Grohmann, R; Häberle, A; Schuhmann, T, 2013) |
| " In this work we will present a 14-year old girl adolescent with psychotic symptoms, in which case the course of treatment and discontinuance of therapy was caused by a side effect - an oculogyric crisis." | 1.36 | The influence of side effect of antipsychotic on the course of treatment in adolescent. ( Dadić-Hero, E; Francisković, T; Graovac, M; Rebić, J; Ruzić, K, 2010) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 1.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "Guidelines for treating schizophrenia have consistently recommended antipsychotic monotherapy." | 1.35 | Combined low-dose clozapine with low-dose aripiprazole in a schizophrenic patient. ( Chen, YY; Hung, GC, 2009) |
| "Because catalepsy is thought to be a good predictor of extrapyramidal symptoms in humans, treatment with orexin-1 antagonists might decrease the occurrence or severity of antipsychotic treatment-emergent extrapyramidal symptoms in humans." | 1.34 | The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. ( Hemrick-Luecke, SK; Hsu, MA; Johnson, BG; Noone, S; Rasmussen, K; Thompson, LK, 2007) |
| " In addition, adverse events were also evaluated." | 1.34 | [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. ( Agoston, T; István, S; Tamás, T; Zoltán, J, 2007) |
| "Risperidone-treated animals showed a catalepsy-like phenotype, which differed to that of haloperidol-treated rats, indicating that processes other than the anticipated dopaminergic mechanisms are underlying this phenomenon." | 1.33 | Behavioural effects of chronic haloperidol and risperidone treatment in rats. ( Dedova, I; Duffy, L; Karl, T; Matsumoto, I; O'brien, E, 2006) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| " Since the estimated risk of the extrapyramidal side effects varied with the dose, the present method of predicting the extrapyramidal side effects of risperidone may provide a basis for developing a rational dosing regimen for the drug." | 1.31 | Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. ( Fukuda, M; Iga, T; Nakashima, Y; Ohno, Y; Sato, H; Sawada, Y; Takayanagi, R; Tsuchiya, F; Yamada, Y, 2002) |
| "Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients." | 1.31 | Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). ( Edgell, E; García-Cabeza, I; Gómez, JC; González de Chavez, M; Sacristán, JA, 2001) |
| "Risperidone was discontinued and clonazepam initiated." | 1.31 | Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. ( Béïque, LC; Bowmer, MI; Kelly, DV, 2002) |
| "Risperidone may prove to be an effective alternative to haloperidol in delirious patients, especially the elderly and the severely medically ill, who are more prone to adverse effects." | 1.30 | Use of risperidone in delirium: case reports. ( Masand, PS; Sipahimalani, A, 1997) |
| "Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors." | 1.30 | Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. ( Heinz, A; Knable, MB; Raedler, T; Weinberger, DR, 1997) |
| "Olanzapine is a new atypical antipsychotic agent that belongs to the same chemical class as clozapine." | 1.30 | In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. ( Dresel, S; Hahn, K; Mager, T; Meisenzahl, E; Möller, HJ; Rossmüller, B; Tatsch, K, 1999) |
| "Risperidone was a useful adjunct in the treatment of agitation and psychosis in outpatients with dementia but was limited by EPS in about one-third of patients." | 1.30 | Risperidone treatment of behavioral disturbances in outpatients with dementia. ( Binetti, G; Ghaemi, SN; Gomez-Isla, T; Growdon, JH; Hyman, BT; Irizarry, MC; Lee-Cherry, ER, 1999) |
| "Risperidone is a recently introduced neuroleptic distinguished by a decreased incidence of extrapyramidal side effects (EPS)." | 1.29 | The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. ( Houle, S; Kapur, S; Remington, G; Wilson, AA; Zipursky, RB, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 56 (25.93) | 18.2507 |
| 2000's | 124 (57.41) | 29.6817 |
| 2010's | 32 (14.81) | 24.3611 |
| 2020's | 4 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Kongsamut, S | 1 |
| Roehr, JE | 1 |
| Cai, J | 1 |
| Hartman, HB | 1 |
| Weissensee, P | 1 |
| Kerman, LL | 1 |
| Tang, L | 1 |
| Sandrasagra, A | 1 |
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Taurines, R | 1 |
| Fekete, S | 1 |
| Preuss-Wiedenhoff, A | 1 |
| Warnke, A | 1 |
| Wewetzer, C | 1 |
| Plener, P | 1 |
| Burger, R | 1 |
| Gerlach, M | 1 |
| Romanos, M | 1 |
| Egberts, KM | 1 |
| Abedini, T | 1 |
| Hosseyni, R | 1 |
| Ghannadi, F | 1 |
| Moghaddam, HS | 1 |
| Ardakani, MK | 1 |
| Talaei, A | 1 |
| Akhondzadeh, S | 3 |
| Salehi, A | 1 |
| Namaei, P | 1 |
| TaghaviZanjani, F | 1 |
| Bagheri, S | 1 |
| Moradi, K | 1 |
| Khodaei Ardakani, MR | 1 |
| Monteleone, P | 1 |
| Cascino, G | 1 |
| Monteleone, AM | 1 |
| Rocca, P | 2 |
| Rossi, A | 1 |
| Bertolino, A | 1 |
| Aguglia, E | 1 |
| Amore, M | 1 |
| Collantoni, E | 1 |
| Corrivetti, G | 1 |
| Cuomo, A | 1 |
| Bellomo, A | 1 |
| D'Ambrosio, E | 1 |
| Dell'Osso, L | 1 |
| Frascarelli, M | 1 |
| Giordano, GM | 1 |
| Giuliani, L | 1 |
| Marchesi, C | 1 |
| Montemagni, C | 2 |
| Oldani, L | 1 |
| Pinna, F | 1 |
| Pompili, M | 1 |
| Roncone, R | 1 |
| Rossi, R | 1 |
| Siracusano, A | 1 |
| Vita, A | 1 |
| Zeppegno, P | 1 |
| Galderisi, S | 1 |
| Maj, M | 1 |
| Pringsheim, T | 1 |
| Ho, J | 1 |
| Sarna, JR | 1 |
| Hammer, T | 1 |
| Patten, S | 1 |
| Biscontri, RG | 1 |
| Jha, S | 1 |
| Collins, DM | 1 |
| Bugden, S | 1 |
| Katz, LY | 1 |
| Alessi-Severini, S | 1 |
| Fuchs, PA | 1 |
| Miller, L | 1 |
| Schiff, M | 1 |
| Elahi, E | 1 |
| Zia, U | 1 |
| Bhutta, OA | 1 |
| Andleeb, S | 1 |
| Vial, T | 1 |
| Patat, AM | 1 |
| Paret, N | 1 |
| Boels, D | 1 |
| Torrents, R | 1 |
| Nisse, P | 1 |
| Villa, A | 1 |
| Kassai, B | 1 |
| Uthayathas, S | 1 |
| Shaffer, CL | 1 |
| Menniti, FS | 1 |
| Schmidt, CJ | 1 |
| Papa, SM | 1 |
| Lammers, L | 1 |
| Zehm, B | 1 |
| Williams, R | 1 |
| Greil, W | 1 |
| Häberle, A | 1 |
| Schuhmann, T | 1 |
| Grohmann, R | 1 |
| Baumann, P | 1 |
| Teranishi, M | 1 |
| Kurita, M | 1 |
| Nishino, S | 1 |
| Takeyoshi, K | 1 |
| Numata, Y | 1 |
| Sato, T | 1 |
| Tateno, A | 1 |
| Okubo, Y | 1 |
| Hutcheson, NL | 1 |
| Clark, DG | 1 |
| Bolding, MS | 1 |
| White, DM | 1 |
| Lahti, AC | 1 |
| Gassó, P | 6 |
| Mas, S | 6 |
| Papagianni, K | 1 |
| Ferrando, E | 1 |
| de Bobadilla, RF | 1 |
| Arnaiz, JA | 1 |
| Bioque, M | 2 |
| Bernardo, M | 6 |
| Lafuente, A | 6 |
| Ritter, MA | 1 |
| Malagelada, C | 1 |
| Parellada, E | 4 |
| Kram, BL | 1 |
| Kram, SJ | 1 |
| Brooks, KR | 1 |
| Boloc, D | 1 |
| Rodriguez, N | 1 |
| Mármol, F | 1 |
| Sánchez, J | 1 |
| Graff-Guerrero, A | 2 |
| Rajji, TK | 1 |
| Mulsant, BH | 4 |
| Nakajima, S | 1 |
| Caravaggio, F | 1 |
| Suzuki, T | 1 |
| Uchida, H | 2 |
| Gerretsen, P | 1 |
| Mar, W | 1 |
| Pollock, BG | 3 |
| Mamo, DC | 2 |
| Bo, QJ | 1 |
| Li, XB | 1 |
| Wang, ZM | 1 |
| Li, AN | 1 |
| Ma, X | 1 |
| Wang, CY | 1 |
| Pérez, CA | 1 |
| Garcia, SS | 1 |
| Yu, RD | 1 |
| Calarge, CA | 1 |
| Murry, DJ | 1 |
| Ziegler, EE | 1 |
| Arnold, LE | 1 |
| Schoretsanitis, G | 1 |
| Haen, E | 1 |
| Hiemke, C | 1 |
| Gründer, G | 1 |
| Stegmann, B | 1 |
| Schruers, KR | 1 |
| Veselinovic, T | 1 |
| Lammertz, SE | 1 |
| Paulzen, M | 1 |
| Heintjes, EM | 1 |
| Overbeek, JA | 1 |
| Penning-van Beest, FJ | 1 |
| Brobert, G | 1 |
| Herings, RM | 4 |
| Reese, TR | 1 |
| Thiel, DJ | 1 |
| Cocker, KE | 1 |
| Kim, E | 1 |
| Correll, CU | 1 |
| Mao, L | 2 |
| Starr, HL | 1 |
| Alphs, L | 1 |
| Haas, M | 1 |
| Karcher, K | 1 |
| Pandina, GJ | 1 |
| Vehof, J | 1 |
| Postma, MJ | 1 |
| Bruggeman, R | 2 |
| De Jong-Van Den Berg, LT | 1 |
| Van Den Berg, PB | 1 |
| Stolk, RP | 1 |
| Burger, H | 1 |
| Peuskens, J | 1 |
| Gillain, B | 1 |
| De Graeve, D | 1 |
| Van Vleymen, B | 1 |
| Albert, A | 1 |
| Kapur, S | 4 |
| Alvarez, S | 1 |
| Okugawa, G | 1 |
| Kato, M | 1 |
| Wakeno, M | 1 |
| Koh, J | 1 |
| Morikawa, M | 1 |
| Matsumoto, N | 1 |
| Shinosaki, K | 1 |
| Yoneda, H | 1 |
| Kishimoto, T | 1 |
| Kinoshita, T | 1 |
| Tchan, MC | 1 |
| Sillence, D | 1 |
| Graovac, M | 1 |
| Ruzić, K | 1 |
| Rebić, J | 1 |
| Dadić-Hero, E | 1 |
| Francisković, T | 1 |
| Glatstein, M | 1 |
| Sulowski, C | 1 |
| Waisburg, C | 1 |
| Koren, G | 1 |
| Garcia-Bournissen, F | 1 |
| Kim, JH | 1 |
| Byun, HJ | 1 |
| Oliveira, C | 1 |
| Trias, G | 1 |
| Comeche, J | 1 |
| Page, CB | 1 |
| Calver, LA | 1 |
| Isbister, GK | 1 |
| Ferentinos, P | 1 |
| Rizos, E | 1 |
| Douzenis, A | 1 |
| Papadopoulou, A | 1 |
| Christodoulou, C | 1 |
| Peppa, M | 1 |
| Lykouras, L | 1 |
| Bret, P | 1 |
| Heil, M | 1 |
| Queuille, E | 1 |
| Bret, MC | 1 |
| Corbeil, P | 1 |
| Rodrigue, J | 1 |
| Simoneau, M | 1 |
| Cohen, H | 1 |
| Pourcher, E | 1 |
| Hakim, SM | 1 |
| Othman, AI | 1 |
| Naoum, DO | 1 |
| Liu, HC | 1 |
| Lin, SK | 1 |
| Sung, SM | 1 |
| Yamada, Y | 2 |
| Ohno, Y | 1 |
| Nakashima, Y | 1 |
| Fukuda, M | 1 |
| Takayanagi, R | 1 |
| Sato, H | 1 |
| Tsuchiya, F | 1 |
| Sawada, Y | 2 |
| Iga, T | 1 |
| Merlo, MC | 1 |
| Hofer, H | 1 |
| Gekle, W | 1 |
| Berger, G | 1 |
| Ventura, J | 1 |
| Panhuber, I | 1 |
| Latour, G | 1 |
| Marder, SR | 4 |
| Yatham, LN | 2 |
| Grossman, F | 3 |
| Augustyns, I | 1 |
| Vieta, E | 3 |
| Ravindran, A | 1 |
| Meibach, RC | 1 |
| Brodaty, H | 2 |
| Ames, D | 1 |
| Snowdon, J | 1 |
| Woodward, M | 1 |
| Kirwan, J | 1 |
| Clarnette, R | 1 |
| Lee, E | 1 |
| Lyons, B | 2 |
| Theodoulou, G | 1 |
| Milner, G | 1 |
| Jumaian, A | 1 |
| Lambert, TJ | 1 |
| Castle, DJ | 1 |
| Zolk, O | 1 |
| Thürauf, N | 1 |
| Potkin, SG | 1 |
| Saha, AR | 1 |
| Kujawa, MJ | 1 |
| Carson, WH | 1 |
| Ali, M | 1 |
| Stock, E | 1 |
| Stringfellow, J | 1 |
| Ingenito, G | 1 |
| Nakagawa, S | 1 |
| Koyama, T | 1 |
| Carlson, CD | 1 |
| Cavazzoni, PA | 1 |
| Berg, PH | 1 |
| Wei, H | 1 |
| Beasley, CM | 1 |
| Kane, JM | 2 |
| Kaneda, Y | 1 |
| Ohmori, T | 1 |
| Weiden, PJ | 1 |
| Daniel, DG | 2 |
| Simpson, G | 1 |
| Romano, SJ | 1 |
| Zalsman, G | 1 |
| Carmon, E | 1 |
| Martin, A | 1 |
| Bensason, D | 1 |
| Weizman, A | 2 |
| Tyano, S | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Zannino, G | 1 |
| Gargiulo, A | 1 |
| Lamenza, F | 1 |
| Marotta, MG | 1 |
| Barzotti, T | 1 |
| Silvestri, A | 1 |
| Ettorre, E | 1 |
| Marigliano, V | 1 |
| Tariot, PN | 2 |
| Profenno, LA | 1 |
| Ismail, MS | 1 |
| Baskys, A | 1 |
| Lejeune, J | 1 |
| Larmo, I | 1 |
| Chrzanowski, W | 1 |
| Witte, R | 1 |
| Karavatos, A | 2 |
| Schreiner, A | 1 |
| Lex, A | 1 |
| Medori, R | 2 |
| Bahk, WM | 3 |
| Yoon, JS | 1 |
| Kim, YH | 1 |
| Lee, YH | 1 |
| Lee, C | 2 |
| Kim, KS | 2 |
| Song, HK | 1 |
| Choi, SK | 2 |
| Pae, CU | 3 |
| Keith, SJ | 1 |
| Pani, L | 1 |
| Nick, B | 1 |
| Emsley, R | 1 |
| San, L | 1 |
| Turner, M | 1 |
| Conley, R | 1 |
| Scully, P | 1 |
| Chue, PS | 1 |
| Lachaux, B | 1 |
| Ciudad, A | 1 |
| Montes, JM | 1 |
| Olivares, JM | 1 |
| Gómez, JC | 3 |
| Aman, MG | 1 |
| Gharabawi, GM | 3 |
| Mintzer, JE | 3 |
| Mullen, JA | 1 |
| Sweitzer, DE | 2 |
| Lang, DJ | 2 |
| Kopala, LC | 4 |
| Vandorpe, RA | 2 |
| Rui, Q | 2 |
| Smith, GN | 2 |
| Goghari, VM | 2 |
| Lapointe, JS | 1 |
| Honer, WG | 4 |
| Lusskin, SI | 1 |
| Cancro, R | 1 |
| Chuang, L | 1 |
| Jacobson, J | 1 |
| Breekveldt-Postma, NS | 1 |
| Schillevoort, I | 3 |
| Nolen, WA | 1 |
| Veraart, CP | 1 |
| Riedel, M | 1 |
| Schwarz, MJ | 1 |
| Strassnig, M | 1 |
| Spellmann, I | 1 |
| Müller-Arends, A | 1 |
| Weber, K | 1 |
| Zach, J | 1 |
| Müller, N | 1 |
| Möller, HJ | 5 |
| Scherer, J | 2 |
| Dobmeier, P | 1 |
| Kuhn, K | 1 |
| Schmaus, W | 1 |
| Malla, A | 1 |
| Norman, R | 1 |
| Scholten, D | 1 |
| Townsend, L | 1 |
| Manchanda, R | 1 |
| Takhar, J | 1 |
| Haricharan, R | 1 |
| Shin, YC | 1 |
| Woo, JM | 1 |
| Yoon, BH | 1 |
| Lee, JS | 1 |
| Jon, DI | 1 |
| Chung, SK | 1 |
| Paik, IH | 1 |
| Bossie, CA | 2 |
| Martinez, RA | 1 |
| Tune, LE | 2 |
| Greenspan, AJ | 1 |
| Bastean, JN | 1 |
| Ren, XS | 1 |
| Huang, YH | 1 |
| Lee, AF | 1 |
| Miller, DR | 1 |
| Qian, S | 1 |
| Kazis, L | 1 |
| de Leon, J | 1 |
| Susce, MT | 1 |
| Pan, RM | 1 |
| Fairchild, M | 1 |
| Koch, WH | 1 |
| Wedlund, PJ | 1 |
| Anil Yağcioğlu, AE | 1 |
| Kivircik Akdede, BB | 1 |
| Turgut, TI | 1 |
| Tümüklü, M | 1 |
| Yazici, MK | 1 |
| Alptekin, K | 1 |
| Ertuğrul, A | 1 |
| Jayathilake, K | 1 |
| Göğüş, A | 1 |
| Tunca, Z | 1 |
| Meltzer, HY | 2 |
| Kakihara, S | 1 |
| Yoshimura, R | 1 |
| Shinkai, K | 1 |
| Matsumoto, C | 1 |
| Goto, M | 1 |
| Kaji, K | 1 |
| Ueda, N | 1 |
| Ohmori, O | 1 |
| Nakamura, J | 1 |
| Keck, PE | 1 |
| Dubois, D | 1 |
| Llorca, PM | 1 |
| Sacchetti, E | 2 |
| Martin, SD | 1 |
| Rabinowitz, J | 1 |
| De Deyn, PP | 2 |
| Katz, IR | 2 |
| Greenspan, A | 2 |
| Burns, A | 1 |
| Matsui-Sakata, A | 1 |
| Ohtani, H | 1 |
| Mendhekar, DN | 1 |
| Kozarić-Kovacić, D | 1 |
| Pivac, N | 1 |
| Mück-Seler, D | 1 |
| Rothbaum, BO | 1 |
| Park, S | 1 |
| Ross-Degnan, D | 1 |
| Adams, AS | 1 |
| Sabin, J | 1 |
| Kanavos, P | 1 |
| Soumerai, SB | 1 |
| Deberdt, WG | 1 |
| Dysken, MW | 1 |
| Rappaport, SA | 1 |
| Feldman, PD | 1 |
| Young, CA | 1 |
| Hay, DP | 1 |
| Lehman, DL | 1 |
| Dossenbach, M | 1 |
| Degenhardt, EK | 1 |
| Breier, A | 2 |
| Arriola, E | 1 |
| Ignacio Diago, J | 1 |
| Antonio Burón, J | 1 |
| Gallego, R | 2 |
| Kurz, A | 1 |
| Schwalen S, S | 1 |
| Schmitt, A | 1 |
| Andersen, TH | 1 |
| Bech, P | 1 |
| Larsen, NE | 1 |
| Durán, JC | 1 |
| Diago, JI | 1 |
| Martinez, G | 1 |
| Preskorn, SH | 1 |
| Rausch, JL | 1 |
| Sirota, EL | 1 |
| Londino, DL | 1 |
| Johnson, ME | 1 |
| Carr, BM | 1 |
| Bhatia, R | 1 |
| Miller, S | 1 |
| Carnahan, RM | 1 |
| Lund, BC | 1 |
| Perry, PJ | 1 |
| Chrischilles, EA | 1 |
| Remington, G | 3 |
| Mamo, D | 1 |
| Labelle, A | 1 |
| Reiss, J | 1 |
| Shammi, C | 1 |
| Mannaert, E | 1 |
| Mann, S | 1 |
| Artaloytia, JF | 1 |
| Arango, C | 1 |
| Lahti, A | 1 |
| Sanz, J | 1 |
| Pascual, A | 1 |
| Cubero, P | 1 |
| Prieto, D | 1 |
| Palomo, T | 1 |
| Bloch, MH | 1 |
| Landeros-Weisenberger, A | 1 |
| Kelmendi, B | 1 |
| Coric, V | 1 |
| Bracken, MB | 1 |
| Leckman, JF | 1 |
| Zhu, Y | 1 |
| Wu, KH | 1 |
| Habil, H | 1 |
| Dyachkova, Y | 1 |
| Lee, P | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Zhong, KX | 1 |
| Hamer, RM | 1 |
| Lieberman, JA | 2 |
| Robinson, DG | 1 |
| Woerner, MG | 1 |
| Napolitano, B | 1 |
| Patel, RC | 1 |
| Sevy, SM | 1 |
| Gunduz-Bruce, H | 1 |
| Soto-Perello, JM | 1 |
| Mendelowitz, A | 1 |
| Khadivi, A | 1 |
| Miller, R | 1 |
| McCormack, J | 1 |
| Lorell, BS | 1 |
| Lesser, ML | 1 |
| Schooler, NR | 2 |
| Tabatabaee, M | 1 |
| Amini, H | 1 |
| Ahmadi Abhari, SA | 1 |
| Abbasi, SH | 1 |
| Behnam, B | 1 |
| Limosin, F | 1 |
| Timdahl, K | 1 |
| Carlsson, A | 1 |
| Stening, G | 1 |
| Rasmussen, K | 1 |
| Hsu, MA | 1 |
| Noone, S | 1 |
| Johnson, BG | 1 |
| Thompson, LK | 1 |
| Hemrick-Luecke, SK | 1 |
| Villari, V | 1 |
| Fonzo, V | 1 |
| Pandullo, P | 1 |
| Bogetto, F | 1 |
| Valsecchi, P | 1 |
| Parrinello, G | 1 |
| Hudson-Jessop, P | 1 |
| Hughes, B | 1 |
| Brinkley, N | 1 |
| Hung, GC | 1 |
| Chen, YY | 1 |
| István, S | 1 |
| Agoston, T | 1 |
| Tamás, T | 1 |
| Zoltán, J | 1 |
| Perez, V | 1 |
| Cañas, F | 1 |
| Tafalla, M | 1 |
| Washburn, CF | 1 |
| Mahmood, T | 1 |
| Clothier, EB | 1 |
| Bridgman, R | 1 |
| Heinrich, K | 1 |
| Klieser, E | 1 |
| Lehmann, E | 1 |
| Kinzler, E | 1 |
| Hruschka, H | 1 |
| Pickar, D | 2 |
| Müller, H | 1 |
| Borison, RL | 1 |
| Chouinard, G | 2 |
| Zipursky, RB | 1 |
| Wilson, AA | 1 |
| Houle, S | 1 |
| McKeith, IG | 1 |
| Ballard, CG | 1 |
| Harrison, RW | 1 |
| Szewczak, MR | 1 |
| Corbett, R | 1 |
| Rush, DK | 1 |
| Wilmot, CA | 1 |
| Conway, PG | 1 |
| Strupczewski, JT | 1 |
| Cornfeldt, M | 1 |
| Vanden Borre, R | 1 |
| Vermote, R | 1 |
| Buttiëns, M | 1 |
| Thiry, P | 1 |
| Dierick, G | 1 |
| Geutjens, J | 1 |
| Sieben, G | 1 |
| Heylen, S | 1 |
| Cesková, E | 1 |
| Svestka, J | 1 |
| Sanderson, DR | 1 |
| Smith, K | 1 |
| Hyde, T | 1 |
| Egan, M | 1 |
| Cheslik, TA | 1 |
| Erramouspe, J | 1 |
| Carter, CS | 2 |
| Sweet, RA | 1 |
| Maxwell, RA | 1 |
| Coley, K | 1 |
| Ganguli, R | 1 |
| Branch, R | 1 |
| Casey, DE | 2 |
| Simpson, GM | 2 |
| Song, F | 1 |
| Lindenmayer, JP | 2 |
| Kirov, GK | 1 |
| Murray, RM | 1 |
| Seth, RV | 1 |
| Feeney, S | 1 |
| Good, KP | 1 |
| Sipahimalani, A | 1 |
| Masand, PS | 2 |
| Zarate, CA | 1 |
| Baldessarini, RJ | 1 |
| Siegel, AJ | 1 |
| Nakamura, A | 1 |
| McDonald, J | 1 |
| Muir-Hutchinson, LA | 1 |
| Cherkerzian, T | 1 |
| Tohen, M | 1 |
| De León, OA | 1 |
| Jobe, TH | 1 |
| Furmaga, KM | 1 |
| Gaviria, M | 1 |
| Franz, M | 1 |
| Lis, S | 1 |
| Plüddemann, K | 1 |
| Gallhofer, B | 1 |
| Knable, MB | 1 |
| Heinz, A | 1 |
| Raedler, T | 1 |
| Weinberger, DR | 1 |
| Pies, R | 1 |
| Davis, JM | 1 |
| Bäuml, J | 1 |
| Ferrero, F | 1 |
| Fuger, J | 1 |
| Geretsegger, C | 1 |
| Kasper, S | 1 |
| Kissling, W | 2 |
| Schubert, H | 1 |
| Miller, CH | 1 |
| Mohr, F | 1 |
| Umbricht, D | 1 |
| Woerner, M | 1 |
| Fleischhacker, WW | 2 |
| Nair, NP | 1 |
| Lavretsky, H | 1 |
| Sultzer, D | 1 |
| Dresel, S | 2 |
| Tatsch, K | 2 |
| Dähne, I | 1 |
| Mager, T | 2 |
| Hahn, K | 2 |
| Magnuson, TM | 1 |
| Keller, BK | 1 |
| Burke, WJ | 1 |
| Iskander, A | 1 |
| Park, M | 1 |
| Apergi, FS | 1 |
| Czobor, P | 1 |
| Smith, R | 1 |
| Allen, D | 1 |
| Travis, MJ | 1 |
| Busatto, GF | 1 |
| Pilowsky, LS | 1 |
| Mulligan, R | 1 |
| Acton, PD | 1 |
| Gacinovic, S | 1 |
| Mertens, J | 1 |
| Terrière, D | 1 |
| Costa, DC | 1 |
| Ell, PJ | 1 |
| Kerwin, RW | 1 |
| Schwartz, M | 1 |
| Beny, A | 1 |
| Sharf, B | 1 |
| Leucht, S | 1 |
| Pitschel-Walz, G | 1 |
| Abraham, D | 1 |
| Breier, AF | 1 |
| Malhotra, AK | 1 |
| Su, TP | 1 |
| Pinals, DA | 1 |
| Elman, I | 1 |
| Adler, CM | 1 |
| Lafargue, RT | 1 |
| Clifton, A | 1 |
| Hawkins, KA | 1 |
| Mohamed, S | 1 |
| Woods, SW | 1 |
| Jeste, DV | 2 |
| Clyde, C | 1 |
| Napolitano, J | 1 |
| Brecher, M | 2 |
| Madhusoodanan, S | 1 |
| Brenner, R | 1 |
| Kasckow, J | 1 |
| Kunik, M | 1 |
| Negrón, AE | 1 |
| Pomara, N | 1 |
| Tandon, R | 1 |
| Milner, K | 1 |
| Jibson, MD | 1 |
| Nyberg, S | 1 |
| Eriksson, B | 1 |
| Oxenstierna, G | 1 |
| Halldin, C | 1 |
| Farde, L | 1 |
| Rossmüller, B | 1 |
| Meisenzahl, E | 1 |
| Irizarry, MC | 1 |
| Ghaemi, SN | 3 |
| Lee-Cherry, ER | 1 |
| Gomez-Isla, T | 1 |
| Binetti, G | 1 |
| Hyman, BT | 1 |
| Growdon, JH | 1 |
| Wirshing, DA | 1 |
| Marshall, BD | 1 |
| Green, MF | 1 |
| Mintz, J | 1 |
| Wirshing, WC | 3 |
| Ananth, J | 1 |
| Burgoyne, K | 1 |
| Aquino, S | 1 |
| Dueñas-Laita, A | 1 |
| Castro-Villamor, MA | 1 |
| Martín-Escudero, JC | 1 |
| Pérez-Castrillon, JL | 1 |
| Coley, KC | 1 |
| DaPos, SV | 1 |
| Maxwell, R | 1 |
| Wilson, JW | 1 |
| Branch, RA | 1 |
| Glazer, WM | 1 |
| Windhaber, J | 1 |
| Urbanits, S | 1 |
| Grisold, W | 1 |
| Conley, RR | 2 |
| de Haan, L | 1 |
| Lavalaye, J | 1 |
| Linszen, D | 1 |
| Dingemans, PM | 1 |
| Booij, J | 1 |
| Sacristán, JA | 2 |
| Montejo, AL | 1 |
| Gregor, KJ | 1 |
| Heeringa, M | 1 |
| Westerink, BH | 1 |
| Timmerman, W | 1 |
| Zaudig, M | 1 |
| Guille, C | 1 |
| Sachs, GS | 2 |
| Heck, AH | 1 |
| Haffmans, PM | 1 |
| de Groot, IW | 1 |
| Hoencamp, E | 1 |
| Spina, E | 1 |
| Avenoso, A | 1 |
| Facciolà, G | 1 |
| Salemi, M | 1 |
| Scordo, MG | 1 |
| Ancione, M | 1 |
| Madia, AG | 1 |
| Perucca, E | 1 |
| Malla, AK | 1 |
| Norman, RM | 1 |
| Scholten, DJ | 1 |
| Zirul, S | 1 |
| Kotteda, V | 1 |
| Mahmoud, R | 1 |
| Buitelaar, JK | 1 |
| van der Gaag, RJ | 1 |
| Cohen-Kettenis, P | 1 |
| Melman, CT | 1 |
| Lemmens, P | 1 |
| van Baelen, B | 1 |
| Bozikas, V | 1 |
| Petrikis, P | 1 |
| Azorin, JM | 1 |
| Spiegel, R | 1 |
| Vanelle, JM | 1 |
| Péré, JJ | 1 |
| Giguere, M | 1 |
| Bourdeix, I | 1 |
| Nishimura, K | 1 |
| Tsuka, M | 1 |
| Horikawa, N | 1 |
| de Boer, A | 2 |
| Roos, RA | 2 |
| Jansen, PA | 2 |
| Leufkens, HG | 2 |
| Herraiz, M | 1 |
| Fernández, A | 1 |
| Gastó, C | 1 |
| Benabarre, A | 1 |
| Colom, F | 1 |
| Martínez-Arán, A | 1 |
| Reinares, M | 1 |
| Davidson, M | 1 |
| Laks, J | 1 |
| Engelhardt, E | 1 |
| Marinho, V | 1 |
| Rozenthal, M | 1 |
| Souza, FC | 1 |
| Bacaltchuk, J | 1 |
| Stoppe, A | 1 |
| Ferreira, RC | 1 |
| Bottino, C | 1 |
| Scalco, M | 1 |
| Buckley, PF | 1 |
| Rainer, MK | 1 |
| Masching, AJ | 1 |
| Ertl, MG | 1 |
| Kraxberger, E | 1 |
| Haushofer, M | 1 |
| Miller, DS | 1 |
| Lam, RW | 1 |
| García-Cabeza, I | 1 |
| Edgell, E | 1 |
| González de Chavez, M | 1 |
| Teoh, L | 1 |
| Allen, H | 1 |
| Kowalenko, N | 1 |
| Hoy, JS | 1 |
| Alexander, B | 1 |
| Kelly, DV | 1 |
| Béïque, LC | 1 |
| Bowmer, MI | 1 |
| Chae, JH | 1 |
| Jun, TY | 1 |
| Kim, DJ | 1 |
| Dickson, RA | 1 |
| Gil-ad, I | 1 |
| Shtaif, B | 1 |
| Shiloh, R | 1 |
| Okamoto, A | 1 |
| Bowden, CL | 1 |
| Gerlach, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Genetic Variations Associated With the Therapeutic Response and Profile of Adverse Effects in the Treatment of Bipolar Depression[NCT04923204] | 76 participants (Actual) | Observational | 2016-03-01 | Completed | |||
| Seroquel Safety Study[NCT01342120] | 18,325 participants (Actual) | Observational | 2010-09-30 | Completed | |||
| A Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia[NCT02918825] | 100 participants (Actual) | Interventional | 2016-09-01 | Completed | |||
| Phase I Clinical Trial. Study of the Impact of Pharmacogenetic Markers in Predicting the Appearance of Extrapyramidal Symptomatology After the Treatment With Typical vs. Atypical Antipsychotics, in Healthy Volunteers[NCT01259973] | Phase 1 | 24 participants (Anticipated) | Interventional | 2011-02-28 | Enrolling by invitation | ||
| The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00250367] | Phase 3 | 151 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial[NCT00249158] | Phase 3 | 344 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130] | 9 participants (Actual) | Interventional | 2016-06-08 | Terminated (stopped due to The study was terminated due to lack of enrollment.) | |||
| Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients[NCT00249171] | Phase 4 | 226 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years[NCT00230893] | 99 participants | Observational | 2005-07-31 | Completed | |||
| Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade[NCT00233467] | 0 participants (Actual) | Observational | 2005-09-01 | Withdrawn (stopped due to Funding expired; no subjects enrolled as this was a retrospective chart review) | |||
| Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564] | Phase 4 | 21 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study[NCT04978428] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-04-14 | Recruiting | ||
| Open Label Study for the Use of Transcranial Ultrasound Treatment of Obsessive-Compulsive Disorder[NCT04775875] | 30 participants (Anticipated) | Interventional | 2020-12-01 | Enrolling by invitation | |||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)[NCT02487966] | 132 participants (Actual) | Interventional | 2015-07-31 | Active, not recruiting | |||
| I-123 Iodobenzamide (IBZM) SPECT Studies of D2 Receptor Distribution and Function in Patients With Schizophrenia and Normal Volunteers[NCT00001320] | 265 participants | Observational | 1991-10-31 | Completed | |||
| Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia[NCT00249132] | Phase 3 | 523 participants (Actual) | Interventional | Completed | |||
| Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled Trial[NCT02639702] | Phase 4 | 30 participants (Anticipated) | Interventional | 2016-08-31 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia[NCT00253123] | Phase 3 | 626 participants (Actual) | Interventional | Completed | |||
| Switching Antipsychotics: Abrupt Discontinuation Versus Overlap[NCT02640300] | Phase 4 | 33 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00253149] | Phase 3 | 158 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
The primary endpoint will be the severity of pain measured by changes in PLP from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS pain scale is a simple 10- point scale (0 = ''no pain'', 10 = ''pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -2.84 |
| Active tDCS and Sham Mirror Therapy | -3.35 |
| Sham tDCS and Active Mirror Therapy | -1.78 |
| Sham tDCS and Sham Mirrory Therapy | -2.58 |
The endpoint will be the severity of pain measured by changes in Phantom Limb Sensation from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Sensation scale is a simple 10- point scale (0 = ''no Phantom Limb Sensation'', 10 = ''Phantom Limb Sensation as much as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -1.86 |
| Active tDCS and Sham Mirror Therapy | -2.55 |
| Sham tDCS and Active Mirror Therapy | -1.35 |
| Sham tDCS and Sham Mirrory Therapy | -2.83 |
The endpoint will be the severity of pain measured by changes in Stump Pain from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Stump Pain scale is a simple 10- point scale (0 = ''no Phantom Limb Stump Pain'', 10 = ''Phantom Limb Stump Pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -1.31 |
| Active tDCS and Sham Mirror Therapy | -1.9 |
| Sham tDCS and Active Mirror Therapy | -0.91 |
| Sham tDCS and Sham Mirrory Therapy | -0.96 |
39 reviews available for risperidone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; | 2016 |
Severe extrapiramidal symptoms after nonintentional risperidone exposure in a child: case report and review of the literature.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Child, Preschool; Humans; Male; Risperidone | 2011 |
Pharmacological approaches to the management of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzothiaze | 2003 |
[Risperidone].
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Dyskinesia, Drug-Induce | 2003 |
[Extrapyramidal syndrome].
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazep | 2003 |
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Ant | 2003 |
Efficacy of atypical antipsychotics in elderly patients with dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric | 2004 |
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical | 2004 |
Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Drug Tolerance; Health Pr | 2004 |
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
Topics: Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Basal Ganglia Dise | 2004 |
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodia | 2005 |
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Cardiomyopathies; Child | 2005 |
Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementia, Vascular; Double-Bl | 2005 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 2006 |
An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chlorproma | 2007 |
Problems with CATIE. Phase 1: Looking back--what the clinician needs to know.
Topics: Antidepressive Agents, Second-Generation; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials, | 2008 |
Serotonin, schizophrenia and antipsychotic drug action.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Isoxazoles; Piperazines; Piperidine | 1995 |
Prospects for pharmacotherapy of schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Isoxazoles; Piperidines; Receptors, | 1995 |
5-HT2 antagonism and EPS benefits: is there a causal connection?
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Receptors, Dopamine D2; Ri | 1996 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials.
Topics: Basal Ganglia Diseases; Humans; Psychiatric Status Rating Scales; Risperidone; Schizophrenia | 1997 |
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Delusions; Depressive Disorder; Hallucinati | 1998 |
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Double-Blind Meth | 1999 |
Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Cognition Disorders; Humans; Reaction Time; | 1999 |
Tardive dyskinesia and atypical antipsychotic drugs.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 1999 |
Antipsychotics from theory to practice: integrating clinical and basic data.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Cl | 1999 |
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brain; Clozapine; Dibenzothiazepines; | 2000 |
Adverse events related to olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In | 2000 |
A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia.
Topics: Aged; Aging; Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Humans; Risk A | 2000 |
Movement disorders associated with neuroleptic treatment.
Topics: Age Factors; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; | 2001 |
Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Con | 2001 |
Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Multicent | 2001 |
Long-term safety of risperidone.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; Clinical Trials as To | 2001 |
Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Cognition | 2001 |
Broad therapeutic uses of atypical antipsychotic medications.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Child Development Disorders, P | 2001 |
New antipsychotics: classification, efficacy, and adverse effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors | 1991 |
77 trials available for risperidone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial.
Topics: Amides; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Double-Bli | 2022 |
Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
Topics: Amides; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Drug Therapy, Combination | 2022 |
Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Basal Ganglia Diseases; Central Nervous System | 2013 |
Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cytochrome P-450 Enzyme System; Gen | 2014 |
Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Drug Administration Schedule; Female; Follow-Up | 2016 |
Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Basal Ganglia Diseases; Bone Density; Cal | 2016 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazep | 2016 |
Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Basal Ganglia | 2008 |
Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Isoindoles; M | 2009 |
Influence of risperidone on balance control in young healthy individuals.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cross-Over Studies; Dose- | 2012 |
Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly: a randomized trial.
Topics: Aged; Anesthesia, General; Antipsychotic Agents; Basal Ganglia Diseases; Cardiopulmonary Bypass; Cri | 2012 |
Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning.
Topics: Acute Disease; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Administration Schedul | 2002 |
Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial.
Topics: Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Brief | 2003 |
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementia, Vascula | 2003 |
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Female; Hosp | 2003 |
Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Gonadal Steroid Hormones; Homovanillic Acid; Hu | 2003 |
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Femal | 2003 |
Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug- | 2003 |
Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aggression; Antipsy | 2004 |
Risperidone in combination with mood stabilizers for acute mania: a multicentre, open study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Asia; Basal Ganglia Diseases; Bipolar Disorder; Drug The | 2004 |
A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepin | 2004 |
Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia; Basal Ganglia Diseases; Benzodiazepines; Cau | 2004 |
Risperidone plasma levels, clinical response and side-effects.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chromatography, High Pressure | 2005 |
[Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone].
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Cross-Sectio | 2004 |
A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorder | 2004 |
Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseas | 2005 |
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorders; Delusions; Demen | 2004 |
A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Double-Blind Method; Drug Administration Sc | 2005 |
Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Female | 2005 |
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaze | 2005 |
Open-label, observational study of the effects of risperidone on the behavioral and psychological symptoms of dementia and caregiver stress in the community setting.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Behavior; Caregivers; Community Health Services; | 2005 |
Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Delusions; Dementia; Female; Humans; | 2005 |
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Buspirone; Denmark; Drug Thera | 2005 |
Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Female; Humans; Mal | 2005 |
Open-label risperidone for Asperger's disorder: negative symptom spectrum response.
Topics: Adolescent; Antipsychotic Agents; Asperger Syndrome; Basal Ganglia Diseases; Child; Diagnostic and S | 2005 |
Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Behavioral Symptoms; Brief Psychiat | 2006 |
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cognition Disorders; Dibenzothiazepines; Disord | 2006 |
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass Index; Female; Follo | 2006 |
Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Basal Ganglia Diseases; Celeco | 2007 |
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Disea | 2008 |
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Drug Admin | 2008 |
A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Drug Administration S | 2008 |
Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Double-Blind Me | 1994 |
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Haloperidol; Hum | 1995 |
Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Drug Therapy, | 1993 |
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Fema | 1993 |
Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Drug Approval; Drug Utilization; Fe | 1995 |
Extrapyramidal symptoms in patients treated with risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Double-Blind Method; Fema | 1997 |
Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergic Antagonists; Drug | 1997 |
Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Male; Psychiatric S | 1997 |
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Double-Blind Meth | 1997 |
Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland.
Topics: Adult; Antipsychotic Agents; Austria; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; | 1997 |
The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antipsychotic Agents; Ba | 1998 |
Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Child; Double-Blind Method; Female; | 1998 |
A structured trial of risperidone for the treatment of agitation in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; Basal Gangli | 1998 |
Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.
Topics: Adult; Basal Ganglia Diseases; Clozapine; Cognition Disorders; Female; Humans; Male; Middle Aged; Ne | 1998 |
Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Clozapine; Double-Blind Method | 1999 |
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases | 1999 |
Risperidone in the treatment of elderly patients with psychotic disorders.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, D | 1999 |
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Dose-Response Rela | 1999 |
Risperidone in treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Cholinergic Ant | 1999 |
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cholinergic Antagonist | 1999 |
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Body Weight; | 2000 |
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Dose-Response Relation | 2000 |
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chromatography, High Pressure | 2001 |
A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Drug Therapy, Combination; Employment; Female; | 2001 |
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 2001 |
A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; B | 2001 |
A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Clozapine; D | 2001 |
Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar | 2001 |
Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly.
Topics: Administration, Oral; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementi | 2001 |
Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Caregivers | 2001 |
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
Topics: Adolescent; Adult; Amenorrhea; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female | 2002 |
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents | 2002 |
New antipsychotics: classification, efficacy, and adverse effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors | 1991 |
101 other studies available for risperidone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Iloperidone binding to human and rat dopamine and 5-HT receptors.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; CHO Cells; Cricetinae; Humans; Isoxazoles; Ki | 1996 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Child; Drug Monitoring; Humans; Pal | 2022 |
Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life".
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Cognition; Female; Humans; Male | 2021 |
Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Child; Drug | 2017 |
Movement Disorders in Children and Adolescents Receiving Antipsychotic Pharmacotherapy: A Population-Based Study.
Topics: Adolescent; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cohort Studies; Female; Humans; Mal | 2017 |
The Use of Carbamazepine to Expedite Metabolism of Risperidone Long-Acting Injection Through Induction of CYP3A4 in a Patient With Extrapyramidal Symptoms.
Topics: Adult; Basal Ganglia Diseases; Carbamazepine; Cytochrome P-450 CYP3A; Delayed-Action Preparations; E | 2018 |
Extrapyramidal symptoms resulting from risperidone use in a four year old child: A case report.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Child, Preschool; Depression; Female; Humans; Risperid | 2018 |
Risperidone medication errors in children: an analysis of French poison centres data.
Topics: Age Factors; Antipsychotic Agents; Basal Ganglia Diseases; Child; Child, Preschool; Dose-Response Re | 2019 |
Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale.
Topics: Algorithms; Animals; Antipsychotic Agents; Autonomic Nervous System; Basal Ganglia Diseases; Behavio | 2013 |
Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Canada; Delayed-Action Prepar | 2013 |
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2013 |
Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia; Basal Ganglia Diseases; Caudate Nucleus; Fem | 2014 |
Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway.
Topics: Adaptor Proteins, Signal Transducing; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Carrier P | 2015 |
Network analysis of gene expression in peripheral blood identifies mTOR and NF-κB pathways involved in antipsychotic-induced extrapyramidal symptoms.
Topics: Adult; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Fema | 2015 |
Implications of atypical antipsychotic prescribing in the intensive care unit.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Benzo | 2015 |
Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Blotting, Western; Disease | 2016 |
Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brain; Carbon Radioisotopes; Fe | 2015 |
Extrapyramidal Symptoms as a Result of Risperidone Discontinuation During Combination Therapy with Methylphenidate in a Pediatric Patient.
Topics: Adolescent; Antipsychotic Agents; Basal Ganglia Diseases; Central Nervous System Stimulants; Drug Th | 2016 |
Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergi | 2016 |
Post authorization safety study comparing quetiapine to risperidone and olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cohort Studies; Female; | 2016 |
Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergic Antagonists; | 2008 |
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Belgium; Benzodiazepines; Brief Psychiatric Rat | 2009 |
Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Case-Control Studies; Cross-S | 2009 |
A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chromosome Mapping; Humans; Linkage Disequilibr | 2009 |
Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.
Topics: Adolescent; Adult; Anticonvulsants; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; C | 2009 |
The influence of side effect of antipsychotic on the course of treatment in adolescent.
Topics: Adolescent; Antipsychotic Agents; Basal Ganglia Diseases; Drugs, Generic; Female; Hospitalization; H | 2010 |
The relationship between akathisia and subjective tolerability in patients with schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Autonomic Nervous System Diseases; Basal Gangl | 2010 |
Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Case-Control Studies; Cohort Studies; Diagnosti | 2011 |
Risperidone overdose causes extrapyramidal effects but not cardiac toxicity.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Databases, Factual; Drug Overdose; | 2010 |
Androgen insensitivity and liability to drug-induced extrapyramidal symptoms.
Topics: Adult; Androgen-Insensitivity Syndrome; Antipsychotic Agents; Basal Ganglia Diseases; Chromosomes, H | 2011 |
[Evaluation of prescription practices of long acting injectable risperidone in French hospitals].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar | 2011 |
Extrapyramidal side-effect due to drug combination of risperidone and donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Donepezil; | 2002 |
Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Humans; Isoxazoles; Models, Biol | 2002 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; | 2003 |
Neuroleptics and family history of Parkinson diseases: case report.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Depressive Disorder; Diagnostic Errors; Female; | 2001 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
The management of psychogeriatric patient.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Ag | 2004 |
Clinical effectiveness of atypical antipsychotics in dementia.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodi | 2004 |
Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.
Topics: Aged; Antipsychotic Agents; Attitude to Health; Basal Ganglia Diseases; Benzodiazepines; Drug Tolera | 2004 |
Prolactin elevation with ziprasidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Comorbidity; Depression, Post | 2004 |
Selective prescribing of atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Antagonists; | 2005 |
Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Antagonists; Chronic Dise | 2005 |
The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cytochrome P-450 CYP2D6; Dose-Response Relation | 2005 |
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Catecholamines; Cen | 2005 |
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical Trials | 2005 |
Rabbit syndrome induced by combined lithium and risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Drug Therapy, Combination; Dy | 2005 |
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzod | 2005 |
Drug-drug interactions: Proof of relevance (Part II): cause of tolerability problems or noncompliance.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 E | 2005 |
Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cross-S | 2006 |
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Corpus Striatum; D | 2006 |
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Haloperidol; Humans; Inciden | 2006 |
Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Asian People; Basal Ganglia Diseases; Benzodiazepines; Diagnostic and S | 2006 |
Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Disease Models, Animal; Dopamine Antagonists; | 2006 |
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Benzodiazepines; Benzoxazol | 2007 |
New for old? Risperidone long-acting injection in older patients.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Female; Humans; Inj | 2007 |
Combined low-dose clozapine with low-dose aripiprazole in a schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Clozapine; Dose-Response Relation | 2009 |
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
Topics: Adult; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzo | 2007 |
Risperidone-induced extrapyramidal reactions.
Topics: Adult; Basal Ganglia Diseases; Dopamine Antagonists; Humans; Male; Risperidone; Schizophrenia | 1995 |
The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Humans; Isoxazoles; Male; Piperidines; Recep | 1995 |
Neuroleptic sensitivity to risperidone in Lewy body dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Female; Humans; Iso | 1995 |
The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Clozap | 1995 |
Drug interaction between risperidone and phenytoin resulting in extrapyramidal symptoms.
Topics: Administration, Oral; Adult; Basal Ganglia Diseases; Drug Administration Schedule; Drug Interactions | 1996 |
Neuroleptic-induced tardive dyskinesia.
Topics: Adolescent; Basal Ganglia Diseases; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fluoxetine; | 1996 |
Extrapyramidal symptoms following accidental ingestion of risperidone in a child.
Topics: Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Child, Preschool; Diphenhydramin | 1996 |
EPS with fever versus NMS.
Topics: Basal Ganglia Diseases; Cholinergic Antagonists; Diagnosis, Differential; Dopamine Agonists; Female; | 1996 |
Use of risperidone in delirium: case reports.
Topics: Adolescent; Antipsychotic Agents; Basal Ganglia Diseases; Delirium; Humans; Male; Middle Aged; Rispe | 1997 |
Risperidone in the elderly: a pharmacoepidemiologic study.
Topics: Age Factors; Aged; Aged, 80 and over; Basal Ganglia Diseases; Cardiovascular Diseases; Comorbidity; | 1997 |
Severe extrapyramidal reaction due to risperidone in a case of neurofibromatosis.
Topics: Basal Ganglia Diseases; Brain Neoplasms; Humans; Male; Middle Aged; Neurofibroma; Neurofibromatoses; | 1997 |
Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Cross-Sectiona | 1997 |
Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Brain Mapping; Dopamine Anta | 1997 |
Re: Extrapyramidal side effects with low-dose risperidone.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Interactions; F | 1997 |
Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Clozapine; Contrast Media; D | 1998 |
Choosing among old and new antipsychotics.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Psychotic Disorders; Receptors, Dop | 1996 |
Extrapyramidal side effects in a patient treated with risperidone plus donepezil.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; Co | 1998 |
5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150.
Topics: Adult; Basal Ganglia Diseases; Clozapine; Female; Humans; Iodine Radioisotopes; Male; Piperidines; R | 1998 |
Risperidone-induced rabbit syndrome.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Mouth Diseases; Risperidone; Syn | 1998 |
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Case-Control Studi | 1999 |
Risperidone treatment of behavioral disturbances in outpatients with dementia.
Topics: Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Re | 1999 |
Meige's syndrome associated with risperidone therapy.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Male; Meige Syndrome; Mental Di | 2000 |
New clinical manifestations of acute risperidone poisoning.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Electrocardiography; Hemodynamics; Humans; Male | 1999 |
Tardive dyskinesia in older patients.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaz | 2000 |
Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Dose-Response Relationship, Drug; Halo | 2000 |
Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance. Dallas, Texas, California. January 22, 1999. Proceedings of a roundtable.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzoth | 2000 |
Side effects of antipsychotics in the elderly.
Topics: Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine | 2000 |
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Corpus | 2000 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Utilizat | 2000 |
Combined 5-HT2/D2 receptor blockade inhibits the firing rate of SNR neurons in the rat brain.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Electrophysiology; Male; Neurons; | 2000 |
An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Basal Ganglia Diseases; Caudate Nucleus; Female; Globus | 2001 |
A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dat | 2001 |
Urinary retention caused after fluoxetine-risperidone combination.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Diseases; Delusions; D | 2001 |
Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Female; Humans; Risperido | 2001 |
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergic Antagonists; Data Colle | 2001 |
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepine | 2001 |
Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
Topics: Adolescent; Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepin | 2001 |
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).
Topics: Adult; Antipsychotic Agents; Attitude to Health; Basal Ganglia Diseases; Benzodiazepines; Female; Ha | 2001 |
Drug-induced extrapyramidal reactions.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Basal Ganglia Diseases; Child; | 2002 |
Rabbit syndrome secondary to risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergic Antagonists; Depressive Disorder, M | 2002 |
Extrapyramidal symptoms with ritonavir/indinavir plus risperidone.
Topics: Acquired Immunodeficiency Syndrome; Adult; Basal Ganglia Diseases; Cytochrome P-450 CYP2D6 Inhibitor | 2002 |
Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Cell Cycle; Cell Survival; Clozapine; | 2001 |
[General practice study with atypical neuroleptics. Differences in tolerance].
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dibenzothiazepines; Family P | 2002 |